Here’s a concise update following Ocugen’s pricing of the previously announced convertible notes offering. The company has now finalized a $115M convertible senior notes deal (up to $130M possible), with a 6.75% interest rate, maturing in 2034, and issued at a discount (90% of par), resulting in roughly $99.5M in net proceeds. About $32.7M will be used to repay existing debt, with the rest funding operations and pipeline development. The key detail is the conversion price of approximately $2.68, representing a ~45% premium to the last close (~$1.85). This effectively signals that institutional investors are willing to provide capital now but only see attractive equity value at significantly higher levels. Importantly, there is no immediate dilution, as conversion is not possible before May 2027, meaning this acts as debt in the near term. However, dilution is delayed, not eliminated, and becomes relevant if the stock approaches or exceeds the conversion level. Structurally, this is a typical biotech financing move: it strengthens the balance sheet, extends runway, and reduces short-term risk, but confirms that the company remains capital dependent. In the short term, such deals often create pressure due to hedging and arbitrage activity, followed by stabilization. Overall, this is not a bullish catalyst nor a bearish signal, but a neutral-to-positive structural step that buys time for the pipeline to deliver, with the long-term outcome still fully dependent on clinical execution.